Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Technology evaluation: T-cell activator, Xenova.

¹University of Washington, Seattle 98195, USA. kknutson@u.washington.edu

Current Opinion in Molecular Therapeutics

|January 24, 2002

Summary

Therapeutic antigen-human papilloma virus (TA-HPV) vaccine shows potential for treating cervical cancer by activating T-cells to target tumor cells. Clinical trials are evaluating its efficacy in patients with high-grade anogenital intraepithelial neoplasia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Evening preference correlates with regional brain volumes in the anterior occipital lobe.

Chronobiology international·2021

Same author

Timing and quality of sleep in a rural Brazilian family-based cohort, the Baependi Heart Study.

Scientific reports·2016

Same author

AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells.

Oncogene·2013

Same author

Sleep disturbance in relation to health-related quality of life in adults: the Fels Longitudinal Study.

The journal of nutrition, health & aging·2009

Same author

Deficiency of heme oxygenase-1 impairs renal hemodynamics and exaggerates systemic inflammatory responses to renal ischemia.

Kidney international·2007

Same author

Augmenting T helper cell immunity in cancer.

Current drug targets. Immune, endocrine and metabolic disorders·2005

Area of Science:

Oncology
Immunology
Vaccinology

Background:

Cervical cancer is frequently associated with human papillomavirus (HPV) DNA in tumor cells.
Therapeutic vaccines aim to stimulate an immune response against cancer cells expressing viral antigens.

Purpose of the Study:

To evaluate the clinical efficacy of TA-HPV vaccine in patients with cervical cancer.
To assess the potential of TA-HPV in treating high-grade anogenital intraepithelial neoplasia.

Main Methods:

Phase IIa clinical trials involving 60 patients with high-grade anogenital intraepithelial neoplasia.
A phase II 'prime-boost' study combining TA-HPV with TA-CIN initiated in the UK.

Main Results:

TA-HPV is under investigation for its ability to activate HPV-specific cytotoxic T-cells.
The vaccine targets tumor cells harboring HPV antigens, a common characteristic in cervical cancer.

Conclusions:

TA-HPV represents a potential therapeutic strategy for cervical cancer.
Ongoing trials will determine the clinical effectiveness of TA-HPV, including combination therapy.

Related Experiment Videos